Literature DB >> 14871430

Validation of serum ferritin values by magnetic susceptometry in predicting iron overload in dialysis patients.

Caterina Canavese1, Daniela Bergamo, Giovannino Ciccone, Filomena Longo, Fabrizio Fop, Alessandra Thea, Guido Martina, Antonio Piga.   

Abstract

BACKGROUND: Guidelines for treating anemia in dialysis patients accept, as high-end range of serum ferritin useful to optimize erythropoietin therapy, values high as 500 to 900 microg/L, on the hypothesis that ferritin might be not representative of iron overload.
METHODS: A superconducting quantum interference device (SQUID) was used to make direct noninvasive magnetic measurements of nonheme hepatic iron content in 40 dialysis patients treated with intravenous iron, and liver iron content was compared with biochemical markers of iron status.
RESULTS: Only 12/40 (30%) patients showed normal hepatic iron content (SQUID <400 microg/g), while 32.5% had mild (400 to 1000 microg/g) and 37.5% severe (>1000 microg/g) iron overload, although 28/40 patients (70%) had serum ferritin below 500 microg/L. Among many parameters, hepatic iron content was only correlated with ferritin (r= 0.324, P= 0.04). The receiver operating characteristic (ROC) analysis showed the best specificity/sensitivity ratio to identify iron overload for ferritin >340 microg/L (W = 0.716). Multivariate logistic regression analysis demonstrated that an increase in serum ferritin of 100 microg/L and female gender were independent variables associated with moderate to severe hepatic iron overload: OR 1.71 (95% CI 1.10 to 2.67) and OR 10.68 (95% CI 1.81 to 63.15), respectively.
CONCLUSION: Hepatic iron overload is frequent in dialysis patients with ferritin below currently proposed high-end ranges, and the diagnostic power of ferritin in indicating true iron stores is better than presumed. Safety concerns should prompt a reevaluation of acceptable iron parameters, focusing on potential gender-specific differences, to avoid potentially harmful iron overload in a majority of dialysis patients, mainly females.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14871430     DOI: 10.1111/j.1523-1755.2004.00480.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  34 in total

1.  Room-temperature susceptometry predicts biopsy-determined hepatic iron in patients with elevated serum ferritin.

Authors:  Bryan D Maliken; William F Avrin; James E Nelson; Jody Mooney; Sankaran Kumar; Kris V Kowdley
Journal:  Ann Hepatol       Date:  2012 Jan-Feb       Impact factor: 2.400

2.  The impact of ferritin fluctuations on stable hemoglobin levels in hemodialysis patients.

Authors:  Mana Yahiro; Takahiro Kuragano; Aritoshi Kida; Rie Kitamura; Minoru Furuta; Yukiko Hasuike; Yoshinaga Otaki; Hiroshi Nonoguchi; Takeshi Nakanishi
Journal:  Clin Exp Nephrol       Date:  2012-01-24       Impact factor: 2.801

3.  Serum iron markers are inadequate for guiding iron repletion in chronic kidney disease.

Authors:  Paolo Ferrari; Hemant Kulkarni; Shyam Dheda; Susanne Betti; Colin Harrison; Timothy G St Pierre; John K Olynyk
Journal:  Clin J Am Soc Nephrol       Date:  2010-09-28       Impact factor: 8.237

Review 4.  Anaemia management and mortality risk in chronic kidney disease.

Authors:  Walter H Hörl
Journal:  Nat Rev Nephrol       Date:  2013-02-26       Impact factor: 28.314

5.  Effect of intravenous iron use on hospitalizations in patients undergoing hemodialysis: a comparative effectiveness analysis from the DEcIDE-ESRD study.

Authors:  Navdeep Tangri; Dana C Miskulin; Jing Zhou; Karen Bandeen-Roche; Wieneke M Michels; Patti L Ephraim; Aidan McDermott; Deidra C Crews; Julia J Scialla; Stephen M Sozio; Tariq Shafi; Bernard G Jaar; Klemens Meyer; L Ebony Boulware
Journal:  Nephrol Dial Transplant       Date:  2014-11-02       Impact factor: 5.992

Review 6.  Considerations and challenges in defining optimal iron utilization in hemodialysis.

Authors:  David M Charytan; Amy Barton Pai; Christopher T Chan; Daniel W Coyne; Adriana M Hung; Csaba P Kovesdy; Steven Fishbane
Journal:  J Am Soc Nephrol       Date:  2014-12-26       Impact factor: 10.121

Review 7.  The Labile Side of Iron Supplementation in CKD.

Authors:  Itzchak Slotki; Zvi Ioav Cabantchik
Journal:  J Am Soc Nephrol       Date:  2015-05-21       Impact factor: 10.121

8.  Cumulative iron dose and resistance to erythropoietin.

Authors:  A Rosati; C Tetta; J I Merello; I Palomares; R Perez-Garcia; F Maduell; B Canaud; P Aljama Garcia
Journal:  J Nephrol       Date:  2014-08-05       Impact factor: 3.902

9.  Intravenous iron exposure and mortality in patients on hemodialysis.

Authors:  Dana C Miskulin; Navdeep Tangri; Karen Bandeen-Roche; Jing Zhou; Aidan McDermott; Klemens B Meyer; Patti L Ephraim; Wieneke M Michels; Bernard G Jaar; Deidra C Crews; Julia J Scialla; Stephen M Sozio; Tariq Shafi; Albert W Wu; Courtney Cook; L Ebony Boulware
Journal:  Clin J Am Soc Nephrol       Date:  2014-10-15       Impact factor: 8.237

10.  The comparative short-term effectiveness of iron dosing and formulations in US hemodialysis patients.

Authors:  Abhijit V Kshirsagar; Janet K Freburger; Alan R Ellis; Lily Wang; Wolfgang C Winkelmayer; M Alan Brookhart
Journal:  Am J Med       Date:  2013-04-15       Impact factor: 4.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.